Strategic Advocates’s Hologic HOLX Stock Holding History

Strategic Advocates’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,458	Closed	-$533K	–	148
2023 Q4	$533K	Buy	7,458 +4,557	+157%	+$317K	0.23%	82
2023 Q3	$201K	Buy	+2,901	New	+$219K	0.09%	136

Other funds holding HOLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Strategic Advocates's HOLX Position: Q1 2024 in Review

Strategic Advocates sold out of Hologic (HOLX) in Q1 2024, closing a stake of 7,458 shares — an estimated $533K sold.

Strategic Advocates first reported a position in HOLX in Q3 2023 and held it in 2 quarters. The position peaked at $533K in Q4 2023. 706 funds tracked by Wall St. Rank hold HOLX as of Q1 2024.

Strategic Advocates reported no remaining Hologic position as of Q1 2024 after selling out during the quarter.
Strategic Advocates sold 7,458 Hologic shares in Q1 2024, an estimated $533K.
Strategic Advocates first reported a position in Hologic in Q3 2023 and held it in 2 quarters.
Strategic Advocates's Hologic position peaked at $533K in Q4 2023.
706 funds tracked by Wall St. Rank held Hologic as of Q1 2024.

Based on Strategic Advocates's 13F filing for Q1 2024, filed 3 Apr 2024.